Previous 10 | Next 10 |
Marinus Pharmaceuticals (NASDAQ: MRNS ) -66% on disappointing ganaxolone data . More news on: Marinus Pharmaceuticals, Inc., LSC Communications, Inc., ACADIA Pharmaceuticals Inc., Stocks on the move, Read more ...
Marinus Pharmaceuticals (NASDAQ: MRNS ) plummets 68% premarket on increased volume in response to results from the second part of a Phase 2 clinical trial, MAGNOLIA, evaluating intravenously administered ganaxolone followed by daily oral ganaxolone in women with postpartum depr...
Second proof-of-concept study for IV ganaxolone with clinically meaningful activity Ganaxolone IV and oral formulations were safe and well-tolerated Future development in severe depressive disorders will focus on IV regimen Conference call and webcast to be held today at 8:00 ...
The following slide deck was published by Marinus Pharmaceuticals, Inc. in conjunction with this Read more ...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 107 weeks of public selections as part of this ongoing live forward-testing. In...
RADNOR, Pa., June 03, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that Dr. Scott Braunstein, executive chairman o...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 104 weeks of public selections as part of this ongoing live forward-testing. In...
Clarifications on the company's leadership transition Chris Cashman's stepping down from his long tenure at the helm of Marinus prompted mixed responses, with some people fearing internal discord or poor prospects for the company's neuroactive investigational drug ganaxolone. I had an oppo...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than five years. This subset of the different portfolios I regularly analyze has now reached 104 weeks of public selections as part of this ongoing live forward-testing. ...
While certainly not always the case, investors ignoring or apathetic to names or sectors can be a sign of looming bullishness. In the cycle of Sentiment, Panic, Capitulation and Despondency often mark the extreme bottoms. However; Depression, Apathy and Indifference are often realized while ...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on August 13, 2024. The Company will h...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schall Law Firm PR Newswire LOS ANGELES , July 24, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing ...
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of ...